Added to YB: 2024-01-02
Pitch date: 2024-01-02
LRMR [bullish]
Larimar Therapeutics, Inc.
-39.61%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Market Cap
$269.6M
Pitch Price
$5.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.71
P/E
-1.61
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
Show full summary:
$LRMR - 50mg has a good shot
$LRMR betting on 50mg for FXN increase, potent dosing & prior data promising; market undervalues therapeutic safety margin. Likely BBB penetration for substantial treatment impact. Q1 awaits 50mg readout.
Read full article (1 min)